Clinical Trials Logo

Uterine Carcinosarcoma clinical trials

View clinical trials related to Uterine Carcinosarcoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05902988 Recruiting - Clinical trials for Advanced Solid Tumor

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

Start date: October 18, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.

NCT ID: NCT05619913 Recruiting - Clinical trials for Uterine Carcinosarcoma

EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma

EPOCH
Start date: May 22, 2023
Phase: Phase 2
Study type: Interventional

The EPOCH study population is patients with tubo-ovarian carcinosarcoma or uterine carcinosarcoma with evidence of recurrence or progression. The study aims to determine the activity of eribulin as a single agent and the combination of eribulin and pembrolizumab as measured by clinical benefit rate (CBR) at 12 weeks. Additionally, the study aims to establish whether high mobility group A2 (HMGA2) protein expression is a good functional biomarker to predict response to eribulin and pembrolizumab.

NCT ID: NCT05147558 Recruiting - Clinical trials for Uterine Carcinosarcoma

A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma

Start date: December 23, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study to find out whether the combination of lenvatinib and pembrolizumab is an effective treatment for advanced uterine carcinosarcoma. The researchers will also do tests to find out whether biomarkers in the blood can predict the cancer's response to the study treatment. A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition

NCT ID: NCT04802876 Recruiting - Clinical trials for Hepatocellular Carcinoma

Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors

ACROPOLI
Start date: April 12, 2021
Phase: Phase 2
Study type: Interventional

This is an open-label, parallel group, non-randomized, multicenter phase II study to evaluate the efficacy of spartalizumab (cohorts 1 and 2) and tislelizumab (cohort 3) in monotherapy in patients with PD1-high-expressing tumors.